Her main research concerns Virology, Integrase, Virus, Viral replication and Integrase inhibitor. She interconnects Acquired immunodeficiency syndrome and Immunology in the investigation of issues within Virology. Her Integrase study integrates concerns from other disciplines, such as Lentivirus and In vitro, Enzyme inhibitor, Enzyme.
Her work focuses on many connections between Viral replication and other disciplines, such as Molecular biology, that overlap with her field of interest in Jurkat cells and Kinase. The Integrase inhibitor study combines topics in areas such as Raltegravir Potassium and Raltegravir. Her Biochemistry research includes themes of Stereochemistry and Amyloid precursor protein.
Her primary scientific interests are in Virology, Integrase, Stereochemistry, Enzyme and Virus. Her Virology research is multidisciplinary, incorporating perspectives in Reverse transcriptase and Immunology. Her Integrase research is multidisciplinary, relying on both Integrase inhibitor, In vitro, Viral replication and Lentivirus.
She usually deals with Integrase inhibitor and limits it to topics linked to Raltegravir and Raltegravir Potassium, Elvitegravir and Pharmacology. Her Enzyme study necessitates a more in-depth grasp of Biochemistry. Her biological study deals with issues like Mutant, which deal with fields such as Mutation.
Her primary areas of study are Virology, Immune system, Immunology, In vivo and Virus. Her work in the fields of Virology, such as Viral replication and Hepatitis C virus, intersects with other areas such as Population. As a part of the same scientific study, Daria J. Hazuda usually deals with the Immunology, concentrating on Antiretroviral therapy and frequently concerns with Pegylated interferon, Pegylated interferon alpha-2b and Persistently infected.
Her In vivo course of study focuses on Cell and Histone deacetylase. Her research integrates issues of Asymptomatic and Mutant in her study of Virus. Her study looks at the relationship between Mutant and topics such as Nucleoside Reverse Transcriptase Inhibitor, which overlap with Molecular biology.
Daria J. Hazuda mostly deals with Virology, Virus, Immune system, Immunology and Virus latency. Her Virology research is multidisciplinary, incorporating elements of Rilpivirine, Mutant and Dose–response relationship. Her research in Virus intersects with topics in Protein subunit, Epitope, Antigen, Immunogenicity and Vaccination.
Vorinostat, Cell killing and Provirus is closely connected to Viral protein in her research, which is encompassed under the umbrella topic of Immune system. Daria J. Hazuda frequently studies issues relating to Asymptomatic and Immunology. Daria J. Hazuda has researched Virus latency in several fields, including Cell, Ex vivo, Histone deacetylase, Panobinostat and T cell.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Inhibitors of Strand Transfer That Prevent Integration and Inhibit HIV-1 Replication in Cells
Daria J. Hazuda;Peter Felock;Marc Witmer;Abigail Wolfe.
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy
N. M. Archin;A. L. Liberty;A. D. Kashuba;S. K. Choudhary.
The challenge of finding a cure for HIV infection.
Douglas D. Richman;David M. Margolis;Martin Delaney;Warner C. Greene.
Raltegravir with Optimized Background Therapy for Resistant HIV-1 Infection
Roy T. Steigbigel;David A. Cooper;Princy N. Kumar;Joseph E. Eron.
The New England Journal of Medicine (2008)
Genome-Scale RNAi Screen for Host Factors Required for HIV Replication
Honglin Zhou;Min Xu;Qian Huang;Adam T. Gates.
Cell Host & Microbe (2008)
Discovery of Raltegravir, a Potent, Selective Orally Bioavailable HIV-Integrase Inhibitor for the Treatment of HIV-AIDS Infection
Vincenzo Summa;Alessia Petrocchi;Fabio Bonelli;Benedetta Crescenzi.
Journal of Medicinal Chemistry (2008)
P-TEFb kinase is required for HIV Tat transcriptional activation in vivo and in vitro.
Helena S.Y. Mancebo;Gary Lee;John Flygare;Joanne Tomassini.
Genes & Development (1997)
Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection.
David A. Cooper;Roy T. Steigbigel;Jose M. Gatell;Jurgen K. Rockstroh.
The New England Journal of Medicine (2008)
Diketo acid inhibitor mechanism and HIV-1 integrase: implications for metal binding in the active site of phosphotransferase enzymes.
Jay A. Grobler;Kara Stillmock;Binghua Hu;Marc Witmer.
Proceedings of the National Academy of Sciences of the United States of America (2002)
Host Cell Factors in HIV Replication: Meta-Analysis of Genome-Wide Studies
Frederic D. Bushman;Nirav Malani;Jason Fernandes;Jason Fernandes;Iván D'Orso;Iván D'Orso.
PLOS Pathogens (2009)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: